Metagenomi Therapeutics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $4M | ↓-59.3% | — | — | — |
| 2025-09-30 | $9M | ↓-24.8% | $-20M | ↓-8.6% | -263.8% |
| 2025-06-30 | $9M | ↓-57.5% | $-20M | ↓-85.4% | -246.5% |
| 2025-03-31 | $4M | ↓-63.0% | $-25M | ↑+0.4% | -674.1% |
| 2024-12-31 | $10M | ↓-22.5% | — | — | — |
| 2024-09-30 | $12M | ↓-6.9% | $-19M | ↑+5.3% | -194.4% |
| 2024-06-30 | $20M | ↑+76.5% | $-11M | ↑+17.4% | -84.3% |
| 2024-03-31 | $11M | ↑+28.9% | $-25M | ↓-55.9% | -260.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$4M
↓-59.3% -$6M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
MGX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyMGX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics